Salvatore Carbone , PhD 1 , 2 , Justin M Canada , MS, RCEP 1 , 3 , Hayley E Billingsley , RD 1 , Dinesh Kadariya , MD 1 , Dave L Dixon , PharmD 4 , Cory R Trankle , MD 1 , Leo F Buckley , PharmD 5 , Roshanak Markley , MD 1 , Chau Vo , MD 1 , Horacio Medina de Chazal , MD 1 , Sanah Christopher , MD 1 , Raffaella Buzzetti , MD 2 , Benjamin W Van Tassell , PharmD 4 , Antonio Abbate , MD, PhD 1
23 April 2018
The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus (T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown.
In this pilot study we determined the effects of empagliflozin10 mg/day for four weeks on peak oxygen consumption (VO 2) in 15 patients with T2DM and HFrEF. As exploratory analysis, we assessed whether there was an interaction for the effects of empagliflozin on peak VO 2 of loop diuretics.
Empagliflozin reduced body weight (−1.7 Kg, p=0.031), but it did not change peak VO 2 (from 14.5 mL•kg −1•min −1 [12.6–17.8] to 15.8 [12.5–17.4] mL•kg −1•min −1, p=0.95). However, patients on loop diuretics (N=9) demonstrated an improvement, whereas those without loop diuretics (N=6) had a decrease in peak VO 2 (+0.9[0.1–1.4] vs −0.9[−2.1– −0.3] mL•kg −1•min −1, p=0.001), and peak VO 2 changes correlated with the baseline daily dose of diuretics (R=+0.83, p<0.001).